Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer

Keita Fujikawa, Yasuo Awakura, Tatsushiro Okabe, Rei Watanabe, Shuzo Nishimura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

(Background) As Bayoumi, et al pointed out in their article (J. Natl. Cancer Inst. 2000, vol 92, p 1731), it is evident that treatment of prostate cancer with Luteinizing Hormone Releasing Hormone (LHRH) analogue costs more than treatment by bilateral orchiectomy. However, patients with metastatic prostate cancer are usually treated with LHRH analogue. Does this mean that urologist choose higher cost and less Quality-Adjusted Life Year (QALY) treatment? Therefore, we urologists should re-analyze their conclusion whether the treatment with LHRH analogue is really strictly dominated (high cost and low effect). (Material and Method) We performed a cost-utility analysis using the Markov model based on a formal meta-analysis and literature review, using the same assumptions as Bayoumi, et al, from the perspective of insurer. The base case was assumed to be a 65-year-old man with symptomatic metastatic prostate cancer. The model used time horizon of 10 years. Five androgen ablation therapies were evaluated as first-line therapy: diethylstilbestrol diphosphate (DES), orchiectomy, orchiectomy + nonsteroidal antiandrogen (NSAA), LHRH analogue and LHRH analogue + NSAA. Outcome measures were QALY, lifetime costs and incremental cost-effectiveness ratios. (Results) While DES was the least expensive therapy with the lowest QALY, LHRH analogue monotherapy was the second most expensive therapy with the longest QALY. Incremental cost-effectiveness ratios relative to DES of LHRH (¥4,288,295/QALY) was cheaper than that of orchiectomy when quality of life (QOL) weight of orchiectomy was assumed to be 0.94 relative to that of LHRH analogue. Contrarily, LHRH analogue + NSAA is excluded with strict dominance and Orchiectomy + NSAA is excluded with extended dominance. (Conclusion) Although LHRH analogue costs higher than orchiectomy, LHRH analogue can offer longer QALY than orchiectomy. Cost/QALY of LHRH analogue relative to DES is ¥4,288,295/ QALY, which we considered to represent a good value. Choice of therapy depends on the patient's preference.

Original languageEnglish
Pages (from-to)503-512
Number of pages10
JournalJapanese Journal of Urology
Volume94
Issue number4
DOIs
Publication statusPublished - 2003 May
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Androgens
Cost-Benefit Analysis
Prostatic Neoplasms
Orchiectomy
Quality-Adjusted Life Years
Nonsteroidal Anti-Androgens
Costs and Cost Analysis
Therapeutics
Insurance Carriers
Patient Preference
Health Care Costs
Meta-Analysis
Quality of Life
Outcome Assessment (Health Care)
Weights and Measures
fosfestrol

Keywords

  • Androgen ablation therapy
  • Prostate cancer
  • Quality adjusted life year

ASJC Scopus subject areas

  • Urology

Cite this

Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer. / Fujikawa, Keita; Awakura, Yasuo; Okabe, Tatsushiro; Watanabe, Rei; Nishimura, Shuzo.

In: Japanese Journal of Urology, Vol. 94, No. 4, 05.2003, p. 503-512.

Research output: Contribution to journalArticle

Fujikawa, Keita ; Awakura, Yasuo ; Okabe, Tatsushiro ; Watanabe, Rei ; Nishimura, Shuzo. / Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer. In: Japanese Journal of Urology. 2003 ; Vol. 94, No. 4. pp. 503-512.
@article{a78c9999051f4ee2880139a2b708df82,
title = "Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer",
abstract = "(Background) As Bayoumi, et al pointed out in their article (J. Natl. Cancer Inst. 2000, vol 92, p 1731), it is evident that treatment of prostate cancer with Luteinizing Hormone Releasing Hormone (LHRH) analogue costs more than treatment by bilateral orchiectomy. However, patients with metastatic prostate cancer are usually treated with LHRH analogue. Does this mean that urologist choose higher cost and less Quality-Adjusted Life Year (QALY) treatment? Therefore, we urologists should re-analyze their conclusion whether the treatment with LHRH analogue is really strictly dominated (high cost and low effect). (Material and Method) We performed a cost-utility analysis using the Markov model based on a formal meta-analysis and literature review, using the same assumptions as Bayoumi, et al, from the perspective of insurer. The base case was assumed to be a 65-year-old man with symptomatic metastatic prostate cancer. The model used time horizon of 10 years. Five androgen ablation therapies were evaluated as first-line therapy: diethylstilbestrol diphosphate (DES), orchiectomy, orchiectomy + nonsteroidal antiandrogen (NSAA), LHRH analogue and LHRH analogue + NSAA. Outcome measures were QALY, lifetime costs and incremental cost-effectiveness ratios. (Results) While DES was the least expensive therapy with the lowest QALY, LHRH analogue monotherapy was the second most expensive therapy with the longest QALY. Incremental cost-effectiveness ratios relative to DES of LHRH (¥4,288,295/QALY) was cheaper than that of orchiectomy when quality of life (QOL) weight of orchiectomy was assumed to be 0.94 relative to that of LHRH analogue. Contrarily, LHRH analogue + NSAA is excluded with strict dominance and Orchiectomy + NSAA is excluded with extended dominance. (Conclusion) Although LHRH analogue costs higher than orchiectomy, LHRH analogue can offer longer QALY than orchiectomy. Cost/QALY of LHRH analogue relative to DES is ¥4,288,295/ QALY, which we considered to represent a good value. Choice of therapy depends on the patient's preference.",
keywords = "Androgen ablation therapy, Prostate cancer, Quality adjusted life year",
author = "Keita Fujikawa and Yasuo Awakura and Tatsushiro Okabe and Rei Watanabe and Shuzo Nishimura",
year = "2003",
month = "5",
doi = "10.5980/jpnjurol1989.94.503",
language = "English",
volume = "94",
pages = "503--512",
journal = "Japanese Journal of Urology",
issn = "0021-5287",
publisher = "Japanese Urological Association",
number = "4",

}

TY - JOUR

T1 - Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer

AU - Fujikawa, Keita

AU - Awakura, Yasuo

AU - Okabe, Tatsushiro

AU - Watanabe, Rei

AU - Nishimura, Shuzo

PY - 2003/5

Y1 - 2003/5

N2 - (Background) As Bayoumi, et al pointed out in their article (J. Natl. Cancer Inst. 2000, vol 92, p 1731), it is evident that treatment of prostate cancer with Luteinizing Hormone Releasing Hormone (LHRH) analogue costs more than treatment by bilateral orchiectomy. However, patients with metastatic prostate cancer are usually treated with LHRH analogue. Does this mean that urologist choose higher cost and less Quality-Adjusted Life Year (QALY) treatment? Therefore, we urologists should re-analyze their conclusion whether the treatment with LHRH analogue is really strictly dominated (high cost and low effect). (Material and Method) We performed a cost-utility analysis using the Markov model based on a formal meta-analysis and literature review, using the same assumptions as Bayoumi, et al, from the perspective of insurer. The base case was assumed to be a 65-year-old man with symptomatic metastatic prostate cancer. The model used time horizon of 10 years. Five androgen ablation therapies were evaluated as first-line therapy: diethylstilbestrol diphosphate (DES), orchiectomy, orchiectomy + nonsteroidal antiandrogen (NSAA), LHRH analogue and LHRH analogue + NSAA. Outcome measures were QALY, lifetime costs and incremental cost-effectiveness ratios. (Results) While DES was the least expensive therapy with the lowest QALY, LHRH analogue monotherapy was the second most expensive therapy with the longest QALY. Incremental cost-effectiveness ratios relative to DES of LHRH (¥4,288,295/QALY) was cheaper than that of orchiectomy when quality of life (QOL) weight of orchiectomy was assumed to be 0.94 relative to that of LHRH analogue. Contrarily, LHRH analogue + NSAA is excluded with strict dominance and Orchiectomy + NSAA is excluded with extended dominance. (Conclusion) Although LHRH analogue costs higher than orchiectomy, LHRH analogue can offer longer QALY than orchiectomy. Cost/QALY of LHRH analogue relative to DES is ¥4,288,295/ QALY, which we considered to represent a good value. Choice of therapy depends on the patient's preference.

AB - (Background) As Bayoumi, et al pointed out in their article (J. Natl. Cancer Inst. 2000, vol 92, p 1731), it is evident that treatment of prostate cancer with Luteinizing Hormone Releasing Hormone (LHRH) analogue costs more than treatment by bilateral orchiectomy. However, patients with metastatic prostate cancer are usually treated with LHRH analogue. Does this mean that urologist choose higher cost and less Quality-Adjusted Life Year (QALY) treatment? Therefore, we urologists should re-analyze their conclusion whether the treatment with LHRH analogue is really strictly dominated (high cost and low effect). (Material and Method) We performed a cost-utility analysis using the Markov model based on a formal meta-analysis and literature review, using the same assumptions as Bayoumi, et al, from the perspective of insurer. The base case was assumed to be a 65-year-old man with symptomatic metastatic prostate cancer. The model used time horizon of 10 years. Five androgen ablation therapies were evaluated as first-line therapy: diethylstilbestrol diphosphate (DES), orchiectomy, orchiectomy + nonsteroidal antiandrogen (NSAA), LHRH analogue and LHRH analogue + NSAA. Outcome measures were QALY, lifetime costs and incremental cost-effectiveness ratios. (Results) While DES was the least expensive therapy with the lowest QALY, LHRH analogue monotherapy was the second most expensive therapy with the longest QALY. Incremental cost-effectiveness ratios relative to DES of LHRH (¥4,288,295/QALY) was cheaper than that of orchiectomy when quality of life (QOL) weight of orchiectomy was assumed to be 0.94 relative to that of LHRH analogue. Contrarily, LHRH analogue + NSAA is excluded with strict dominance and Orchiectomy + NSAA is excluded with extended dominance. (Conclusion) Although LHRH analogue costs higher than orchiectomy, LHRH analogue can offer longer QALY than orchiectomy. Cost/QALY of LHRH analogue relative to DES is ¥4,288,295/ QALY, which we considered to represent a good value. Choice of therapy depends on the patient's preference.

KW - Androgen ablation therapy

KW - Prostate cancer

KW - Quality adjusted life year

UR - http://www.scopus.com/inward/record.url?scp=0038659056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038659056&partnerID=8YFLogxK

U2 - 10.5980/jpnjurol1989.94.503

DO - 10.5980/jpnjurol1989.94.503

M3 - Article

C2 - 12795165

AN - SCOPUS:0038659056

VL - 94

SP - 503

EP - 512

JO - Japanese Journal of Urology

JF - Japanese Journal of Urology

SN - 0021-5287

IS - 4

ER -